3 completed, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Clinically Significant Portal Hypertension: new trials by email Literature Review of Clinically Significant Portal Hypertension trials Research Report on Clinically Significant Portal Hypertension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss Transjugular Intrahepatic Portosystemic Shunt, Non-selective beta-blockers - Liver Cirrhosis, Clinically Significant Portal Hypertension | Not applicable | Recruiting | Medical University of Warsaw | 104 | 2025-06-24 | 2025-08-08 |
| Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial Experimental group: Patients will be treated with carvedilol., Control group: Patients will receive a placebo. - Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension | Phase 3 | Not yet recruiting | University Hospital, Tours | 290 | 2025-06-17 | 2025-06-04 |
| The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension supress the night dose of carvedilol - Clinically Significant Portal Hypertension | Not applicable | Completed | Centro Hospitalar De São João, E.P.E. | 34 | 2023-06-01 | 2023-08-29 |
| Assessment of Portal Hypertension With Multiparametric MRI mpMRI, ARFI US - Portal Hypertension, Clinically Significant Portal Hypertension | Completed | Icahn School of Medicine at Mount Sinai | 69 | 2018-03-20 | 2023-03-06 | |
| The Effect of Sorafenib on Portal Pressure Placebo, Sorafenib - Clinically Significant Portal Hypertension | Phase 2 | Completed | Yale University | 10 | 2011-08-01 | 2020-12-29 |
Hypertension, Portal (3) · Liver Cirrhosis (2) · Death (1)
Digestive System Diseases (4) · Liver Diseases (4) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Fibrosis (2)
Carvedilol (1) · Portasystemic Shunt, Transjugular Intrahepatic (1) · Sorafenib (1)
Centro Hospitalar De São João, E.P.E. (1) · Icahn School of Medicine at Mount Sinai (1) · Medical University of Warsaw (1) · University Hospital, Tours (1) · Yale University (1)
United States (2) · France (1) · Poland (1) · Portugal (1)
Bachir Taouli, MD (1) · Guadalupe Garcia-Tsao, MD (1)
R01DK113272 (1)